Benjamin Kelmendi

Benjamin Kelmendi is a clinical researcher affiliated with contemporary academic programmes in psychedelic science, including contributions linked to the Yale Program for Psychedelic Science. His published and in‑progress work spans early‑phase human pharmacology, translational neurobiology and qualitative/attitudinal research relevant to the clinical deployment of psychedelic and entactogenic compounds.

Key contributions include authorship on preclinical and human‑focused manuscripts investigating methylone as a rapid‑acting entactogen and putative neuroplastogen with anxiolytic and antidepressant‑like effects, comparative pharmacology of methylone versus MDMA, and a case report with SPECT imaging and a theoretical rationale for sequential ibogaine and 5‑MeO‑DMT administration in alcohol use disorder. Kelmendi has also co‑authored work on mechanisms of therapeutic change following psychedelic treatment in obsessive‑compulsive disorder and on palliative care provider attitudes toward existential distress and psychedelic‑assisted therapies. His output reflects interdisciplinary engagement across neuropharmacology, substance use disorders and the evolving clinical frameworks for psychedelic interventions.